All Stories

  1. Unraveling gait and balance impairment in cervical dystonia: associated features, functional implications, and the effect of botulinum toxin
  2. Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant
  3. Early Detection of Dysphagia Signs in Parkinson’s Disease: An Artificial Intelligence-Based Approach Using Non-Invasive Sensors
  4. Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease
  5. Identifying Poor Responders to STN DBS in Parkinson Disease: The Role of Rapid Disease Progression in the First Year in Optimal Responders to Levodopa
  6. Reply: “Human Pose Estimation Is Approximate: Limitations and Considerations for its Use in Clinical Trials”
  7. Dynamic Video Assessment of Axial Postural Abnormalities in Parkinson's Disease: A Pilot Study
  8. Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial
  9. Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life
  10. Neurological symptoms in adults with Gaucher disease: a systematic review
  11. Botulinum Toxin for Axial Postural Abnormalities in Parkinson’s Disease: A Systematic Review
  12. CACNA1A variant associated with generalized dystonia
  13. Unveiling the Unpredictable in Parkinson’s Disease: Sensor-Based Monitoring of Dyskinesias and Freezing of Gait in Daily Life
  14. Subthalamic and Nigral Stimulation for Freezing of Gait in Parkinson disease: randomized pilot trial
  15. Longitudinal Assessment of Botulinum Toxin Treatment for Lateral Trunk Flexion and Pisa Syndrome in Parkinson’s Disease: Real-life, Long-Term Study
  16. Predictors and Pathophysiology of Axial Postural Abnormalities in Parkinsonism: A Scoping Review
  17. Filling the Gap in Assessing Pain in Dystonia
  18. Deep Brain Stimulation Outcomes in Parkinson's Disease Patients with Cognitive Impairment: Implications and Considerations
  19. Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management
  20. The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
  21. Camera- and Viewpoint-Agnostic Evaluation of Axial Postural Abnormalities in People with Parkinson’s Disease through Augmented Human Pose Estimation
  22. Assessment of Axial Postural Abnormalities in Parkinsonism: Automatic Picture Analysis Software
  23. Visuospatial Deficits are associated with Pisa Syndrome and not Camptocormia in Parkinson's disease
  24. Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study
  25. Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety
  26. Time to onset and duration of botulinum toxin efficacy in movement disorders
  27. Standardized Biomechanical Investigation of Posture and Gait in Pisa Syndrome Disease
  28. Early reversible leukoencephalopathy and unilateral sixth cranial nerve palsy in mild COVID-19 infection
  29. G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome
  30. Comment on: “Point of view: Wearable systems for at-home monitoring of motor complications in Parkinson's disease should deliver clinically actionable information”
  31. Deep brain stimulation outcomes in the malignant end of Parkinson's disease spectrum
  32. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review
  33. Speech Impairment in Parkinson’s Disease: Acoustic Analysis of Unvoiced Consonants in Italian Native Speakers
  34. Deep Brain Stimulation Selection Criteria for Parkinson’s Disease: Time to Go beyond CAPSIT-PD
  35. COVID-19 in Parkinson's disease: Report on prevalence and outcome
  36. Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail
  37. Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on Dyskinesia
  38. Neurological comorbidity and severity of COVID-19
  39. Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential
  40. Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications
  41. Smartphone-Based Evaluation of Postural Stability in Parkinson’s Disease
  42. Tuning Deep Brain Stimulation related depression by frequency modulation: a case report
  43. Should We Consider Deep Brain Stimulation Discontinuation in Late‐Stage Parkinson's Disease?
  44. Changing the Side of Pisa Syndrome: A Case of Over‐Recovery with Botulinum Toxin
  45. Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?
  46. Video analysis of long-term effects of levodopa-carbidopa intestinal gel on gait and posture in advanced Parkinson’s disease
  47. Differential response to pallidal deep brain stimulation among monogenic dystonias: systematic review and meta-analysis
  48. Smartphone-Based Estimation of Leg Agility in People With Parkinson's Disease
  49. Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease
  50. Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors
  51. Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study
  52. Home monitoring of motor fluctuations in Parkinson’s disease patients
  53. Telemedicine in Neurological Disorders: Opportunities and Challenges
  54. Complex therapies for advanced Parkinson’s disease: what is the role of doctor-patient communication?
  55. Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease: A Neurocognitive Approach
  56. Pisa Syndrome in Parkinson's Disease Is Associated With Specific Cognitive Alterations
  57. Long‐term effect of levodopa‐carbidopa intestinal gel on axial signs in Parkinson’s disease
  58. Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study
  59. Effect of subthalamic deep brain stimulation on posture in Parkinson's disease: A blind computerized analysis
  60. Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study
  61. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease
  62. Levodopa‐Induced Neuropathy: A Systematic Review
  63. Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
  64. Cardiovascular autonomic neuropathy and falls in Parkinson disease: a prospective cohort study
  65. Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation
  66. Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects
  67. Deep brain stimulation in uncommon tremor disorders: indications, targets, and programming
  68. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease
  69. Orthostatic hypotension in Parkinson disease: Impact on health care utilization
  70. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases
  71. Subthalamic deep brain stimulation and trunk posture in Parkinson's disease
  72. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy
  73. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis
  74. Natalizumab in Multiple Sclerosis: Long-Term Management
  75. Prevalence and burden of dysautonomia in advanced Parkinson's disease
  76. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
  77. The still under-investigated role of cognitive deficits in PML diagnosis
  78. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
  79. Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
  80. Parkinsonism–hyperpyrexia syndrome and deep brain stimulation
  81. Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia
  82. Earlier versus later subthalamic deep brain stimulation in Parkinson's disease
  83. Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients
  84. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience
  85. Medical therapy and subthalamic deep brain stimulation in advanced Parkinson's disease: a different long-term outcome?
  86. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients
  87. 80 Hz versus 130 Hz subthalamic nucleus deep brain stimulation: Effects on involuntary movements
  88. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study
  89. Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients: A 15 months follow-up study
  90. Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset?
  91. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease
  92. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients